Scholar Rock Holding (SRRK) EBITDA (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly EBITDA of -$102.0 million for Q1 2026, down 32.33% year-over-year from -$150.8 million in Q1 2025, and down 11.01% quarter-over-quarter from -$91.9 million in Q4 2025.
Scholar Rock Holding (SRRK) EBITDA (2017 - 2026) Analysis & Trends
Scholar Rock Holding's EBITDA history runs 10 years deep, the most recent figure standing at -$102.0 million for Q1 2026.
- In Q1 2026, EBITDA fell 32.33% year-over-year to -$102.0 million; the TTM figure through Mar 2026 stood at -$409.6 million (down 51.29% YoY), while the FY2025 annual figure was -$384.6 million, down 52.6% from the prior year.
- EBITDA for Q1 2026 stood at -$102.0 million, down from -$91.9 million in the prior quarter.
- The five-year high for EBITDA was -$6.9 million in Q1 2022, with the low at -$112.1 million in Q2 2025.
- The 5-year median for EBITDA is -$58.4 million (2024), against an average of -$61.4 million.
- The sharpest annual moves came in 2022 and 2023: EBITDA jumped 74.52% in 2022, then plunged 484.29% in 2023.
- Scholar Rock Holding's EBITDA stood at -$40.4 million in 2022, then declined by 18.81% to -$48.0 million in 2023, then slumped by 44.4% to -$69.4 million in 2024, then slumped by 32.5% to -$91.9 million in 2025, then decreased by 11.01% to -$102.0 million in 2026.
- Business Quant data shows SRRK's EBITDA at -$102.0 million in Q1 2026, -$91.9 million in Q4 2025, and -$103.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | -108.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -108.90 Mn |
| Mar 31, 2026 | -102.02 Mn |
| Dec 31, 2025 | -91.90 Mn |
| Sep 30, 2025 | -103.55 Mn |
| Jun 30, 2025 | -112.11 Mn |
| Mar 31, 2025 | -77.09 Mn |
| Dec 31, 2024 | -69.36 Mn |
| Sep 30, 2024 | -64.78 Mn |
| Jun 30, 2024 | -59.50 Mn |
| Mar 31, 2024 | -58.42 Mn |
| Dec 31, 2023 | -48.03 Mn |
| Sep 30, 2023 | -43.67 Mn |
| Jun 30, 2023 | -39.08 Mn |
| Mar 31, 2023 | -40.51 Mn |
| Dec 31, 2022 | -40.43 Mn |
| Sep 30, 2022 | -43.86 Mn |
| Jun 30, 2022 | -43.15 Mn |
| Mar 31, 2022 | -6.93 Mn |
| Dec 31, 2021 | -35.36 Mn |
| Sep 30, 2021 | -37.08 Mn |